Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.

Michael Markus Bonelli Daniel MrakSelma TobudicDaniela SieghartMaximilian KoblischkePeter MandlBarbara KornekElisabeth SimaderHelga RadnerThomas Perkmann Helmuth HaslacherMargareta MayerPhilipp HoferKurt RedlichEmma Husar-MemmerRuth Fritsch-StorkRenate ThalhammerKarin StiasnyStefan WinklerJosef S SmolenJudith H AberleMarkus ZeitlingerLeonhard X Heinz Daniel Aletaha

Published in: Annals of the rheumatic diseases (2022)

This enhanced humoral and/or cellular immune response supports an additional booster vaccination in non-seroconverted patients irrespective of a heterologous or homologous vaccination regimen.

Keyphrases

immune response
end stage renal disease
sars cov
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
dna repair
oxidative stress
dendritic cells
patient reported outcomes
toll like receptor
binding protein